Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030049851 A1
Publication typeApplication
Application numberUS 10/156,462
Publication date13 Mar 2003
Filing date28 May 2002
Priority date7 Jun 1995
Also published asCA2380622A1, CA2380622C, EP1200837A1, EP1200837A4, US6429017, WO2001013125A1
Publication number10156462, 156462, US 2003/0049851 A1, US 2003/049851 A1, US 20030049851 A1, US 20030049851A1, US 2003049851 A1, US 2003049851A1, US-A1-20030049851, US-A1-2003049851, US2003/0049851A1, US2003/049851A1, US20030049851 A1, US20030049851A1, US2003049851 A1, US2003049851A1
InventorsCheng Toh, Colin Downey, Timothy Fischer
Original AssigneeToh Cheng Hock, Colin Downey, Fischer Timothy J.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method for predicting the presence of haemostatic dysfunction in a patient sample
US 20030049851 A1
Abstract
A method which may be used to determine haemostatic dysfunction in a patient is carried out by (a) adding a reagent to a test sample, wherein the test sample includes at least a component of a blood sample from a patient; and then (b) measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, the reagent forming a precipitate in the test sample without causing substantial fibrin polymerization.
Images(28)
Previous page
Next page
Claims(76)
We claim:
1. A method comprising:
a) adding a reagent to a test sample comprising at least a component of a blood sample from a patient;
b) measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, said reagent capable of forming a precipitate in the test sample without causing substantial fibrin polymerization.
2. The method according to claim 1, wherein said reagent comprises a metal ion.
3. The method according to claim 2, wherein said metal ion is a divalent metal ion.
4. The method according to claim 3, wherein said divalent metal ion is a metal ion from the transition elements.
5. The method according to claim 2, wherein said metal ion comprises one or more of calcium, magnesium, manganese, iron or barium.
6. The method according to claim 1, wherein a clot inhibitor is provided as part of said reagent or as part of an additional reagent added to said test sample.
7. The method according to claim 6, wherein said clot inhibitor comprises one or more of hirudin, heparin, PPACK, I2581, and antithrombin.
8. The method according to claim 1, wherein the formation of said precipitate is correlated to the existence of haemostatic dysfunction in the patient.
9. The method according to claim 8, wherein the greater the formation of said precipitate, the worse the existence of haemostatic dysfunction in the patient which can be quantified by constructing a reference curve to compare said patient test sample with previous patient samples.
10. The method according to claim 1, wherein the time dependent measurement profile is an optical transmission profile, and wherein the greater the decrease in transmission in the test sample, the greater the formation of said precipitate, and the greater the haemostatic dysfunction in the patient.
11. The method according to claim 1, wherein said precipitate comprises a protein weighing approximately 20 kD.
12. The method according to claim 11, wherein said protein is insoluble in saline, EDTA and Imidazole, and soluble in 5 molar urea.
13. The method according to claim 1, wherein said reagent is added to said test sample in the absence of clot inducing reagents.
14. The method according to claim 1, wherein the formation of the precipitate is measured at least once after time_0.
15. The method according to claim 14, wherein a single endpoint measurement is made of precipitate formation after time_0.
16. The method according to claim 1, wherein said reagent is capable of causing precipitate formation completely in the absence of fibrin polymerization.
17. The method according to claim 10, wherein the amount of fibrin polymerization in the method, if any, causes no change in optical transmittance.
18. A method for determining whether or not a patient has haemostatic dysfunction, comprising:
a) obtaining a blood sample from a patient;
b) obtaining plasma from said blood sample;
c) adding a reagent capable of inducing the formation of a precipitate in patients with haemostatic dysfunction without causing any substantial fibrin polymerization;
d) taking one or more measurements of a parameter of the sample wherein changes in the sample parameter are capable of correlation to precipitate formation if present;
e) determining that a patient has haemostatic dysfunction if precipitate formation is detected.
19. The method according to claim 18, wherein a plurality of measurements are made after addition of said reagent.
20. The method according to claim 18, wherein a single reagent is used prior to taking said measurements.
21. The method according to claim 18, wherein said measurements are measurements of optical transmission or absorbance through said sample.
22. The method according to claim 21, wherein said reagent comprises a metal ion.
23. The method according to claim 22, wherein said metal ion comprises one or more of calcium, magnesium, manganese, iron or barium.
24. The method according to claim 18, wherein a clot inhibitor is provided as part of said reagent or as part of an additional reagent added to said test sample.
25. The method according to claim 24, wherein said clot inhibitor comprises one or more of hirudin, heparin, PPACK, I2581 or antithrombin.
26. The method according to claim 18, wherein said one or more measurements are unaffected by clot formation due to lack of fibrin polymerization.
27. The method according to claim 18, wherein the one or more measurements are a plurality of measurements, and wherein a rate of change of said plurality of measurement is determined, and wherein haemostatic dysfunction is determined based on the determined rate of change.
28. The method according to claim 18, wherein said haemostatic dysfunction is DIC.
29. A method for determining a patient sample the presence of a complex of proteins comprising at least one of serum amyloid A and C-reactive protein, comprising:
a) obtaining a test sample from a patient;
b) adding an alcohol, a clot inhibitor, and a metal cation;
wherein a precipitate is formed which comprises a complex of proteins including at least one of serum amyloid A and C-reactive protein.
30. The method according to claim 29, wherein said patient test sample is a sample of whole blood or a portion thereof.
31. The method according to claim 30, wherein said alcohol is methanol or ethanol.
32. The method according to claim 30, wherein said metal ion is a divalent metal cation selected from the group consisting of calcium magnesium, manganese, iron and barium, and wherein said clot inhibitor is selected from the group consisting of hirudin, heparin, PPACK, I2581 and antithrombin.
33. A method comprising:
a) adding a coagulation reagent to an aliquot of a test sample from a patient;
b) monitoring the formation of fibrin over time in said test sample by measuring a parameter of said test sample which changes over time due to addition of said coagulation reagent;
c) determine a rate of change, if any, of said parameter in a period of time prior to formation of fibrin in said test sample;
d) if said determined rate of change is beyond a predetermined threshold, then with a second aliquot of said patient test sample, add thereto a reagent that induces the formation of a precipitate in the absence of fibrin polymerization;
e) measuring the formation of the precipitate over time; and
f) determining the possibility or probability of haemostatic dysfunction based on the measurement of the precipitate.
34. The method according to claim 33, wherein said coagulation reagent is a PT reagent or an APTT reagent.
35. The method according to claim 34, wherein said reagent that causes precipitate formation is a divalent metal cation.
36. The method according to claim 35, wherein said divalent metal cation is calcium, magnesium, manganese, iron or barium.
37. The method according to claim 35, wherein said reagent that causes precipitate formation comprises a clot inhibitor.
38. The method according to claim 37, wherein said clot inhibitor is hirudin, heparin, PPACK, I2581 or antithrombin.
39. The method according to claim 33, wherein at least one measurement in the test of the second aliquot with the reagent capable of forming a precipitate without causing fibrin polymerization is at a time greater than the clotting time of the first aliquot.
40. A method for monitoring an inflammatory condition in a patient, comprising:
a) adding a reagent to a patient test sample, said reagent capable of causing precipitate formation in some patient test samples without causing fibrin polymerization;
b) measuring a parameter of said test sample over time which is indicative of said precipitate formation;
c) determining the slope of said changing parameter;
d) repeating steps a) to c) at a later date or time;
wherein an increase or decrease in said slope at said later date or time is indicative of progression or regression, respectively, of said inflammatory condition.
41. The method according to claim 40, wherein a plurality of measurements are taken over time so as to provide the slope of said changing parameter.
42. The method according to claim 40, wherein said reagent comprises a metal divalent cation.
43. The method according to claim 42, wherein said reagent comprises calcium, magnesium, manganese, iron or barium.
44. The method according to claim 42, wherein said reagent further comprises a clot inhibitor.
45. The method according to claim 44, wherein said clot inhibitor is heparin, hirudin, PPACK, I2581 or antithrombin.
46. The method according to claim 40, wherein said changing parameter is optical transmission or absorbance.
47. The method according to claim 40, wherein said inflammatory condition is one or more of rheumatoid arthritis, sepsis, or a condition due to surgery of trauma.
48. A method for diagnosing and treating patients with haemostaic dysfunction, comprising:
a) adding a reagent to a test sample that causes precipitate formation without causing fibrin polymerization;
b) taking measurements over time of a parameter of the test sample that changes due to the formation of the precipitate;
c) determining the rate of change of said parameter;
d) determining that a patient has haemostatic dysfunction if said rate of change is beyond a predetermined limit;
e) intervening with treatment for said haemostatic dysfunction if said rate of change is beyond the predetermined limit.
49. The method according to claim 48, wherein said treatment includes administration of antibiotics and/or clot inhibitors.
50. The method according to claim 48, wherein said treatment comprises identifying and correcting the underlying cause of said haemostatic dysfunction.
51. The method according to claim 50, wherein said treatment comprises the administration of a broad spectrum antibiotic, evacuation of the uterus in abruptio placentae, blood replacement therapy, administration of platelet concentrates to correct thrombocytopenia, administration of fresh plasma, administration of one or more blood factors, and/or treatment with interleukin-1.
52. The method according to claim 48, wherein said haemostatic dysfunction is DIC or haemostatic dysfunction with the potential to lead to DIC.
53. The method according to claim 48, further comprising repeating steps a) to d) at one or more later times or dates, comparing the later one or more rates of change of the parameter with the earlier, and optimizing treatment based on increases or decreases in the rates of change of the parameter.
54. The method according to claim 53, wherein said changing parameter is changing optical transmittance through the test sample.
55. The method according to claim 54, wherein the test sample is whole blood or a portion thereof.
56. The method according to claim 55, wherein said test sample is a plasma sample.
57. The method according to claim 48, wherein said reagent that causes the precipitate formation in the absence of fibrin polymerization comprises a divalent metal cation.
58. The method according to claim 57, wherein said reagent comprises barium, iron, manganese, magnesium and/or calcium.
59. The method according to claim 57, wherein said reagent further comprises a clot inhibitor.
60. The method according to claim 59, wherein said clot inhibitor is antithrombin, I2581, PPACK, heparin and/or hirudin.
61. A method comprising:
a) adding a reagent to a patient sample capable of causing formation of a precipitate in said sample;
b) monitoring a changing parameter of said sample over time, said parameter indicative of said precipitate formation;
C) determining the rate of change of said parameter or whether said parameter exceeds a predetermined limit at a predetermined time;
d) repeating steps a) to c) at least once, each time at a different plasma/reagent ratios;
e) measuring the maximum, average and/or standard deviation for the measurements in step c); and
f) determining haemostatic dysfunction based on measurements of step e).
62. The method according to claim 61, further comprising repeating steps a) to e) at a later time or date to monitor disease progression or regression.
63. The method according to claim 61, wherein said haemostatic dysfunction is DIC or haemostatic dysfunction with the potential to lead to DIC.
64. The method according to claim 61, wherein said reagent further comprises a clot inhibitor.
65. The method according to claim 64, wherein said reagent comprises a metal cation capable of inducing precipitate formation.
66. The method according to claim 65, wherein said reagent comprises calcium, magnesium, manganese, iron or barium as divalent cations.
67. The method according to claim 61, wherein said different plasma/reagent ratios are a result of altering the concentration of said reagent from test to test.
68. The method according to claim 61, wherein said different plasma/reagent ratios are a result of altering the concentration of said test sample from test to test.
69. The method according to claim 68, wherein said test sample is a plasma sample that is diluted at different ratios from test to test.
70. An immunoassay comprising:
a) providing a ligand capable of binding to C-reactive protein or the 300 kD protein in lane 5 of FIG. 21;
b) adding said ligand to a test sample from a patient and allowing binding of said ligand to C-reactive protein or said 300 kD protein in said test sample;
c) detecting the presence and or amount of C-reactive protein or said 300 kD protein in said sample; and
d) diagnosing haemostatic dysfunction in the patient due to the detection and/or amount of C-reactive protein or said 300 kD protein detected.
71. The immunoassay of claim 70, wherein said C-reactive protein or said 300 kD protein detected is part of a complex of proteins formed upon addition of a metal divalent cation to the test sample.
72. The immunoassay of claim 71, wherein said complex of proteins comprises both CRP and said 300 kD protein and further comprises serum amyloid A.
73. The immunoassay of claim 70, wherein said haemostatic dysfunction diagnosed is DIC or haemostatic dysfunction with the potential to lead to DIC.
74. The immunoassay according to claim 71, wherein the diagnosed haemostatic dysfunction has the potential to lead to bleeding or thrombosis.
75. The immunoassay of claim 71, wherein said C-reactive protein is modified, cleaved, mutated or whole C-reactive protein.
76. A method for testing the efficacy of a new drug on a human or animal subject with an inflammatory condition and/or haemostatic dysfunction, comprising:
a) adding a reagent to a patient test sample, said reagent capable of causing precipitate formation in some subject test samples without causing fibrin polymerization;
b) measuring a parameter of said test sample over time which is indicative of said precipitate formation;
c) determining the slope of said changing parameter and/or the value of said parameter at a predetermined time;
d) administering a drug to said animal or human subject;
e) repeating steps a) to c) at a later date or time;
wherein an increase or decrease in said slope or value at said later date or time is indicative of the efficacy of said drug.
Description
  • [0001]
    This application is a continuation-in-part of U.S. patent application Ser. No. 09/244,340, filed Feb. 4, 1999, the subject matter of which is incorporated herein by reference. This application also relates to U.S. Pat. No. 5,646,046 to Fischer et al., the subject matter of which is incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Blood clots are the end product of a complex chain reaction where proteins form an enzyme cascade acting as a biologic amplification system. This system enables relatively few molecules of initiator products to induce sequential activation of a series of inactive proteins, known as factors, culminating in the production of the fibrin clot. Mathematical models of the kinetics of the cascade's pathways have been previously proposed.
  • [0003]
    Thrombosis and hemostasis testing is the in vitro study of the ability of blood to form clots and to break clots in vivo. Coagulation (hemostasis) assays began as manual methods where clot formation was observed in a test tube either by tilting the tube or removing fibrin strands by a wire loop. The goal was to determine if a patient's blood sample would clot after certain materials were added. It was later determined that the amount of time from initiation of the reaction to the point of clot formation in vitro is related to congenital disorders, acquired disorders, and therapeutic monitoring. In order to remove the inherent variability associated with the subjective endpoint determinations of manual techniques, instrumentation has been developed to measure clot time, based on (1) electromechanical properties, (2) clot elasticity, (3) light scattering, (4) fibrin adhesion, and (5) impedance. For light scattering methods, data is gathered that represents the transmission of light through the specimen as a function of time (an optical time-dependent measurement profile).
  • [0004]
    Two assays, the PT and APTT, are widely used to screen for abnormalities in the coagulation system, although several other screening assays can be used, e.g. protein C, fibrinogen, protein S and/or thrombin time. If screening assays show an abnormal result, one or several additional tests are needed to isolate the exact source of the abnormality. The PT and APTT assays rely primarily upon measurement of time required for clot time, although some variations of the PT also use the amplitude of the change in optical signal in estimating fibrinogen concentration.
  • [0005]
    Blood coagulation is affected by administration of drugs, in addition to the vast array of internal factors and proteins that normally influence clot formation. For example, heparin is a widely-used therapeutic drug that is used to prevent thrombosis following surgery or under other conditions, or is used to combat existing thrombosis. The administration of heparin is typically monitored using the APTT assay, which gives a prolonged clot time in the presence of heparin. Clot times for PT assays are affected to a much smaller degree. Since a number of other plasma abnormalities may also cause prolonged APTT results, the ability to discriminate between these effectors from screening assay results may be clinically significant.
  • [0006]
    The present invention was conceived of and developed for predicting haemostatic dysfunction in a sample based on one or more time-dependent measurement profiles, such as optical time-dependent measurement profiles. In addition, the present invention is directed to predicting the presence of Disseminated Intravascular Coagulation in a patient based on a time-dependent profile, such as an optical transmission profile, from an assay run on the patient's blood or plasma sample.
  • SUMMARY OF THE INVENTION
  • [0007]
    The present invention is directed to a method for detecting a precipitate in a test sample in the absence of clot formation. The method includes providing a test sample and adding thereto a reagent, the reagent alone or in combination with additional reagents causing the formation of a precipitate. The reagent preferably comprises a metal divalent cation and optionally includes a clot inhibiting substance. The detection of the precipitate can be qualitative or quantitative, and the precipitate can be detected such as by a clotting assay, a latex agglutination or gold sol assay, an immunoassay such as an ELISA, or other suitable method that would allow for detection and/or quantitation of the precipitate. The formation of the precipitate can be detected as an endpoint value, or kinetically. This precipitate detection allows for predicting Haemostatic Dysfunction in patients. The present invention is useful for predicting Haemostatic Dysfunction that can lead to bleeding or thrombosis, or specifically to Disseminated Intravascular Coagulation (DIC).
  • [0008]
    More particularly, the present invention is directed to a method comprising adding a reagent to a test sample having at least a component of a blood sample from a patient, measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, the reagent capable of forming a precipitate in the test sample without causing substantial fibrin polymerization. The invention is also directed to a method for determining whether or not a patient has haemostatic dysfunction, comprising obtaining a blood sample from a patient, obtaining plasma from said blood sample, adding a reagent capable of inducing the formation of a precipitate in patients with haemostatic dysfunction without causing any substantial fibrin polymerization, taking one or more measurements of a parameter of the sample wherein changes in the sample parameter are capable of correlation to precipitate formation if present, and determining that a patient has haemostatic dysfunction if precipitate formation is detected.
  • [0009]
    The present invention is also directed to a method for determining in a patient sample the presence of a complex of proteins comprising at least one of a 300 kD protein, serum amyloid A and C-reactive protein, comprising obtaining a test sample from a patient, adding an alcohol, a clot inhibitor, and a metal cation, wherein a precipitate is formed which comprises a complex of proteins including at least one of a 300 kD protein, serum amyloid A and C-reactive protein.
  • [0010]
    The invention is also directed to a method comprising adding a coagulation reagent to an aliquot of a test sample from a patient, monitoring the formation of fibrin over time in said test sample by measuring a parameter of the test sample which changes over time due to addition of the coagulation reagent, determine a rate of change, if any, of said parameter in a period of time prior to formation of fibrin in said test sample, if the determined rate of change is beyond a predetermined threshold, then with a second aliquot of the patient test sample, add thereto a reagent that induces the formation of a precipitate in the absence of fibrin polymerization, measuring the formation of the precipitate over time, and determining the possibility or probability of haemostatic dysfunction based on the measurement of the precipitate.
  • [0011]
    The invention is also directed to a method for monitoring an inflammatory condition in a patient, comprising adding a reagent to a patient test sample, the reagent capable of causing precipitate formation in some patient test samples without causing fibrin polymerization, measuring a parameter of the test sample over time which is indicative of said precipitate formation, determining the slope of the changing parameter, repeating he the above steps at a later date or time, wherein an increase or decrease in the slope at the later date or time is indicative of progression or regression, respectively, of the inflammatory condition.
  • [0012]
    The invention is further directed to a method for diagnosing and treating patients with haemostaic dysfunction, comprising adding a reagent to a test sample that causes precipitate formation without causing fibrin polymerization, taking measurements over time of a parameter of the test sample that changes due to the formation of the precipitate, determining the rate of change of said parameter, determining that a patient has haemostatic dysfunction if said rate of change is beyond a predetermined limit; intervening with treatment for said haemostatic dysfunction if said rate of change is beyond the predetermined limit.
  • [0013]
    The invention also is directed to a method comprising adding a reagent to a patient sample capable of causing formation of a precipitate in said sample, monitoring a changing parameter of said sample over time, said parameter indicative of said precipitate formation, determining the rate of change of said parameter or whether said parameter exceeds a predetermined limit at a predetermined time, repeating the above steps at least once, each time at a different plasma/reagent ratios, measuring the maximum, average and/or standard deviation for the measurements; and determining haemostatic dysfunction based on the maximum, average and/or standard deviation measurements.
  • [0014]
    The present invention is further directed to an immunoassay comprising providing a ligand capable of binding to C-reactive protein or the 300 kD protein in lane 5 of FIG. 21, adding said ligand to a test sample from a patient and allowing binding of said ligand to C-reactive protein or said 300 kD protein in said test sample, detecting the presence and or amount of C-reactive protein or said 300 kD protein in said sample, and diagnosing haemostatic dysfunction in the patient due to the detection and/or amount of C-reactive protein or said 300 kD protein detected.
  • [0015]
    The invention further relates to a method for testing the efficacy of a new drug on a human or animal subject with an inflammatory condition and/or haemostatic dysfunction, comprising adding a reagent to a patient test sample, said reagent capable of causing precipitate formation in some subject test samples without causing fibrin polymerization, measuring a parameter of said test sample over time which is indicative of said precipitate formation, determining the slope of said changing parameter and/or the value of said parameter at a predetermined time, administering a drug to said animal or human subject, repeating the above steps at a later date or time, wherein an increase or decrease in said slope or value at said later date or time is indicative of the efficacy of said drug.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    [0016]FIGS. 1a and 1 b illustrate transmittance waveforms on the APTT assay with FIG. 1a showing a normal appearance, and 1 b showing a biphasic appearance;
  • [0017]
    [0017]FIG. 2 illustrates transmittance levels at 25 seconds in relation to diagnosis in 54 patients with bi-phasic waveform abnormalities. The horizontal dotted line represents the normal transmittance level;
  • [0018]
    [0018]FIG. 2 illustrates transmittance levels (upper panel) and waveforms (lower panel) on a patient who developed DIC following sepsis and recovered;
  • [0019]
    [0019]FIG. 4 illustrates serial transmittance levels (upper panel) and waveforms (lower panel) on a patient who developed DIC following trauma and died;
  • [0020]
    [0020]FIG. 5 illustrates ROC plots for the prediction of DIC transmittance at 25 seconds (TR25), APTT clot time, and slope_1 (the slope up to the initiation of clot formation);
  • [0021]
    [0021]FIGS. 6 and 7 show histograms for DIC, normal and abnormal/non-DIC populations for TR25 and slope_1;
  • [0022]
    [0022]FIGS. 8 and 10 show group distributions for slope_1 and TR25 respectively;
  • [0023]
    [0023]FIGS. 9 and 11 show partial subpopulations of the data shown in FIGS. 8 and 10;
  • [0024]
    [0024]FIG. 12 is an optical transmission profile for an APTT assay;
  • [0025]
    [0025]FIGS. 13 and 14 are optical transmission profiles for PT assays;
  • [0026]
    [0026]FIG. 15 is an illustration of two waveforms where (x) is a test run on a sample using an APTT clotting reagent and resulting in a biphasic waveform, and (y) is a test run where a clot inhibitor is used;
  • [0027]
    [0027]FIG. 16 is a standard curve for ELISA of CRP;
  • [0028]
    [0028]FIG. 17 shows an isolated precipitate after gel filtration;
  • [0029]
    [0029]FIG. 18 is a graph showing the time course of turbidity in a sample upon adding a precipitate inducing reagent;
  • [0030]
    [0030]FIG. 19 is a graph showing the relationship between maximum turbidity change and amount of patient plasma in a sample;
  • [0031]
    [0031]FIG. 20 shows the results of anion exchange chromatography of material recovery after fractionation of patient plasma;
  • [0032]
    [0032]FIGS. 21a and 21 show the non-reduced and reduced SDS page of various fractions of patient plasma;
  • [0033]
    [0033]FIG. 22 shows immunoblots of CRP in normal and DIC plasma;
  • [0034]
    [0034]FIG. 23 illustrates the turbidity change upon adding divalent calcium to materials obtained upon Q-sepharose chromatography in the absence of plasma (except top curve);
  • [0035]
    [0035]FIG. 24 is a table showing CRP determined by ELISA;
  • [0036]
    [0036]FIG. 25 shows the response to increasing calcium concentrations in optical transmission profiles;
  • [0037]
    [0037]FIG. 26 shows a more pronounced slope without the use of a clotting agent;
  • [0038]
    [0038]FIG. 27 is a calibration curve with heparin;
  • [0039]
    [0039]FIG. 28 shows CRP levels in 56 ITU patients plotted against transmittance at 18 seconds; and
  • [0040]
    [0040]FIG. 29 shows more samples with CRP and decrease in transmittance at 18 seconds (10000-TR18).
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0041]
    In the present invention, not only can a particular abnormality (Haemostatic Dysfunction) be detected, but in addition the progression of the disease can be monitored in a single patient. Haemostatic Dysfunction, as used herein, is a condition evidenced by the formation of a precipitate prior to (or in the absence of clot formation, depending upon the reagent used).
  • [0042]
    Disseminated intravascular coagulation (DIC—a type of Haemostatic Dysfunction) prognosis has been hampered by the lack of an early, useful and rapidly available diagnostic marker. The invention has been found to be not only useful as an early diagnostic and single monitoring marker of DIC, but in addition the quantifiable and standardizable changes also allow for prognostic applicability in clinical management.
  • [0043]
    Disseminated intravascular coagulation (DIC) is a secondary response to a pre-existing pathology whereby the haemostatic response becomes perturbed and disseminated as opposed to the focused events of normal haemostasis. Despite improvements both in the intensive care management of patients and in our basic knowledge of haemostatic mechanisms in DIC, survival in this patient group is still very discouraging. Fundamental to the management of this complication is the implementation of aggressive therapy directed at forestalling or eradicating the primary pathology as the source of the initiating stimulus. However, in practical terms, the problem remains one of early identification of DIC to facilitate immediate and appropriate intervention. Although the technological armory available to the clinical investigator has expanded enormously, the pace of acute DIC precludes most of the more specific tests and reliance is still placed on traditional screening tests such as the prothrombin (PT), activated partial thromboplastin time (APTT) and platelet count. These tests lack specificity on an individual basis and are only useful in DIC if they lead on to further determinations of fibrinogen and fibrin breakdown products/D-dimers. However, changes in these parameters may not occur all at the same time and as such, serial testing is often needed which inevitably leads to a delay in diagnosis and clinically useful intervention.
  • [0044]
    The normal sigmoidal appearance from an APTT transmittance waveform (TW) changes to a “bi-phasic” appearance in DIC patients. This represents a loss in the plateau of a normal APTT-TW, with development of an initial low gradient slope followed by a much steeper slope (FIGS. 1a and b). In addition, this bi-phasic pattern can be seen even when the APTT clotting time result is normal.
  • [0045]
    Freshly collected blood samples that required a PT or an APTT were analyzed prospectively over a two week working period. These were in 0.105M tri-sodium citrate in the ratio of 1 part anticoagulant to 9 parts whole blood and the platelet-poor plasma was analyzed on the MDA (Multichannel Discrete Analyzer) 180, an automated analyzer for performing clinical laboratory coagulation assays using an optical detection system (Organon Teknika Corporation, Durham, N.C., USA). In addition, to deriving the clot times for both PT (normal 11.2-15s) using MDA Simplastin LS and APTT (normal 23-35s) using MDA Platelin LS with 0.025M calcium chloride (Organon Teknika Corporation, USA), an analysis of the TW for the APTT was performed on each occasion at a wavelength of 580 nm. To quantitate the visual profile, the amount of light transmittance at 25 seconds was recorded. A normal waveform has a light transmittance of 100% that is represented on the analyzer and in FIG. 1a without the decimal point as 10000. As such, a bi-phasic change will have a reduced light transmittance of less than 10000. As can be seen in FIG. 1b, decreasing levels of light transmittance prior to clot formation correlate directly with increasing steepness of the bi-phasic slope. The recording of the light transmittance at 25 seconds also allows for standardization between patients and within the same patient with time. If the minimum level of light transmittance for each sample were to be used instead, this would be affected by variations in the clot time of the APTT and would therefore not be ideal for comparisons.
  • [0046]
    To ensure that no cases of DIC were overlooked, the following criteria was followed. If (a) an abnormal bi-phasic TW was encountered, or (b) a specific DIC screen was requested, or (c) if there was a prolongation in either the PT or APTT in the absence of obvious anticoagulant therapy, a full DIC screen was performed. This would further include the thrombin time (TT) (normal 10.5-15.5 seconds), fibrinogen (Fgn) (normal 1.5-3.8 g/l) and estimation of D-dimer levels (normal <0.5 mg/l) on the Nyocard D-Dimer (Nycomed Pharma AS, Oslo, Norway). Platelet counts (Plt) (normal 150-400 109/l) performed on an EDTA sample at the same time were recorded. In addition, clinical details were fully elucidated on any patient with a bi-phasic TW or coagulation abnormalities consistent with DIC.
  • [0047]
    The diagnosis of DIC was strictly defined in the context of both laboratory and clinical findings of at least 2 abnormalities in the screening tests (increased PT, increased APTT, reduced Fgn, increased TT or reduced Plt) plus the finding of an elevated D-dimer level (>0.5 mg/l) in association with a primary condition recognized in the pathogenesis of DIC. Serial screening tests were also available on those patients to chart progression and confirmation of the diagnosis of DIC as was direct clinical assessment and management. For statistical analysis, values for the sensitivity, specificity, positive and negative prediction of the APTT-TW for the diagnosis of DIC were calculated employing a two-by-two table. 95% confidence intervals (CI) were calculated by the exact binomial method.
  • [0048]
    A total of 1,470 samples were analyzed. These were from 747 patients. 174 samples (11.9%) from 54 patients had the bi-phasic waveform change. 22 of these 54 patients had more than 3 sequential samples available for analysis. DIC was diagnosed in 41 patients with 30 of these requiring transfusion support with fresh frozen plasma, cryoprecipitate or platelets. The underlying clinical disorders as shown in Table 1
    TABLE 1
    Clinical disorders predisposing patients to DIC.
    Disorder No
    Infections 17
    Trauma or recent major surgery 16
    Malignancy 2
    Hepatic Disease 1
    Obstetric Cause 1
    Miscellaneous Additional Causes * 4
  • [0049]
    40 of the 41 patients with DIC had the bi-phasic TW. The one false negative result (DIC without a bi-phasic TW) occurred in a patient with pre-eclampsia (PET) where the single sample available for analysis showed a prolonged PT of 21.0s, APTT of 44.0s and raised D-dimers of 1.5 mg/l. 5 other patients were identified in this study with PET and none had either DIC or a bi-phasic TW. Of the 14 patients with a bi-phasic TW which did not fulfil the criteria of DIC, all had some evidence of a coagulopathy with abnormalities in one or two of the screening tests. These abnormal results fell short of the criterion for DIC as defined above. 4 of these 14 patients had chronic liver disease with prolonged PT and mild thrombocytopaenia. A further 2 patients had atrial fibrillation with isolated elevation of D-dimer levels only. The remaining 8 patients were on the ICU with multiple organ dysfunction arising from trauma or suspected infection but without the classical laboratory changes of DIC. These patient profiles were described in the ICU as consistent with the “systemic inflammatory response syndrome” (SIRS). Based on these figures, the bi-phasic TW has a 97.6% sensitivity for the diagnosis of DIC with a specificity of 98%. Use of an optical transmittance waveform was found to be helpful in detecting the biphasic waveform.
    TABLE 2
    Performance of the transmittance waveform (TW) analysis
    in patients with and without DIC
    Biphasic Normal
    TW TW Total
    DIC positive 40  1  41
    DIC negative 14 692 706
    Total 54 693 747
  • [0050]
    The positive predictive value of the test was 74%, which increased with increasing steepness of the bi-phasic slope and decreasing levels of light transmittance (Table 2 and FIG. 2). In the first two days of the study, there were 12 patients who had an abnormality in the clotting tests plus elevation of D-dimer levels. These were patients who were clinically recovering from DIC that occurred in the week preceding the study. This led to the impression that TW changes might correlate more closely with clinical events than the standard markers of DIC.
    TABLE 3
    Serial results in a patient with sepsis
    Pit
    PT APTT TT Fgn D-Dimer (150-400
    Day Time (11.2-15 s) (23-35 s) (10.5-15.5 s) (1.5-3.8 g/l) (<0.5 mg/l) 109/l) TW
    1 0923 14.7 32.9 12.0 4.7 0.00 193  B*
    1 2022 20.8* 38.6* 12.4 5.7 6.00*  61*  B*
    2 0920 18.0* 33.0 13.0 5.2 2.00*  66* N
    3 1011 16.3* 24.8 13.2 4.7 0.00  64* N
  • [0051]
    The availability of more than 3 sequential samples in 22 patients allowed for further assessment. Table 3 illustrates one such example with serial test results from a patient with E. coli septicaemia.
  • [0052]
    The appearance of a bi-phasic TW preceded changes in the standard tests for the diagnosis of DIC. It was only later in the day that the PT, APTT, Plt and D-dimer levels became abnormal and fulfilled the diagnostic criteria of DIC. Treatment with intravenous antibiotics led to clinical improvement by Day 2 with normalization of her TW in advance of the standard parameters of DIC. D-dimers and Plt were still respectively abnormal 24 and 48 hours later.
  • [0053]
    This correlation between clinical events and TW changes was seen in all the DIC patients where samples were available to chart the course of clinical events. As the TW changes were quantifiable and standardizable through recording of the transmittance level at 25 seconds, this analysis provided a handle in assessing prognostic applicability. FIG. 3 illustrates the results of a patient who initially presented with peritonitis following bowel perforation. This was further complicated by gram negative septicaemia post-operatively with initial worsening of DIC followed by a gradual recovery after appropriate therapy. As DIC progressed initially, there was increasing steepness in the bi-phasic slope of the TW and a fall in the light transmittance level. A reversal of this heralded clinical recovery. FIG. 4 illustrates the results of a patient who sustained severe internal and external injuries following a jet-ski accident. Although initially stabilized with blood product support, his condition deteriorated with continuing blood loss and development of fulminant DIC. The bi-phasic slope became increasingly steep with falls in transmittance level as the consequences of his injuries proved fatal.
  • [0054]
    As DIC can arise from a variety of primary disorders, the clinical and laboratory manifestations can be extremely variable not only from patient to patient but also in the same patient with time. There is therefore, a need for systems that are not only robust in their diagnosis but simple and rapid to perform. Although it has been shown that the bi-phasic TW appeared to be sensitive for Haemostatic Dysfunction (e.g. DIC) and was not seen in other selected patient groups with coagulation aberrations or influenced by either (i) pre-analytical variables, (ii) different silica-based APTT reagents, (iii) the use of thrombin as the initiator of the coagulation reaction or (iv) treatment in the form of heparin or plasma expanders, the robustness of this assay for DIC could only be addressed through a prospective study. This study has shown that the bi-phasic TW provides diagnostic accuracy in DIC with an overall sensitivity of 97.6% and specificity of 98%. In contrast, none of the standard parameters on an individual basis (i.e., PT, APTT, TT, Fgn, Plt, D-dimers) or even in combination, has ever reached the degree of sensitivity or specificity. The ready availability of TW data from the MDA-180 would also fulfil the criteria of simplicity and rapidity unlike the measurements of thrombin-antithrombin complexes or other markers that are dependent on ELISA technology. In addition, the advantages of TW analysis are that: (a) the bi-phasic TW change appears to be the single most useful correlate within an isolated sample for DIC and as such, reliance need no longer be placed on serial estimations of a battery of tests, and (b) the appearance or resolution of the bi-phasic TW can precede changes in the standard, traditional parameters monitored in DIC with strong, clear correlation to clinical events and outcome.
  • [0055]
    Although the bi-phasic TW was also seen in patients who did not have DIC per se as defined by the above criteria, the clinical conditions were associated with Haemostatic Dysfunction—namely activated coagulation prior to initiation of clot formation resulting in a biphasic waveform (for example in chronic liver disease or in the very ill patients on the Intensive Care Unit who had multiple organ dysfunction). It appears that bi-phasic TW is sensitive to non-overt or compensated DIC and that a transmittance level of less than 90% (FIG. 2) or sequential falls in that level (FIG. 4), reflects decompensation towards a more overt manifestation and potentially fulminant form of DIC. This line of explanation is supported by the observation of only a mild bi-phasic TW (transmittance level of about 95%) in 2 patients with atrial fibrillation; a condition that is associated with mild coagulation activation and elevated D-dimer levels. As no follow-up samples were available on these 2 patients whose clinical details were otherwise unremarkable, their bi-phasic TW could well have been transient. Nonetheless, these cases illustrate that the lower the level of light transmittance, the more likely the bi-phasic TW becomes predictive of Haemostatic Dysfunction, particularly DIC.
  • [0056]
    The observation of a normal TW in a patient with PET and DIC needs further exploration as the study did not selectively aim to examine any particular patient groups and only had a total of 6 patients with PET; the remaining 5 of which did not have DIC. One explanation which would be supported by other findings in this study is that the patient could have been recovering from PET and DIC at the time of the sample. There may already have been normalization in the bi-phasic TW in advance of the other parameters which were still abnormal and indicative of DIC. Another explanation is that the disturbed haemostatic process in PET is more localized and different from the DIC that arises from other conditions. Such patients respond dramatically to delivery of the fetus which suggests anatomical localization of the pathological process to the placenta despite standard laboratory clotting tests implying systemic evidence of the condition.
  • EXAMPLE
  • [0057]
    Though analysis of the transmittance at a time of 25 seconds is helpful in predicting DIC, a second embodiment of the invention has been found that greatly improves sensitivity and specificity. It has been found that looking at transmittance at a particular time can result in detecting an artifact or other decrease in transmittance at that point, even though the waveform is not a bi-phasic waveform. For example, a temporary dip in transmittance at 25 seconds would cause such a patient sample to be flagged as bi-phasic, even if the waveform was normal or at least not bi-phasic. Also, if a patient sample had a particularly short clotting time, then if clot formation begins e.g. prior to 25 seconds (or whatever time is preselected), then the waveform could be flagged as biphasic, even though the real reason for decreased transmittance at 25 seconds is because clot formation has already begun/occurred.
  • [0058]
    For this reason, it has been found that rather than analysis of transmittance at a particular time, it is desirable to calculate the slope of the waveform prior to initiation of clot formation. This calculation can involve determination of clot time followed by determination of waveform slope prior to clot time. In an additional embodiment, the slope (not transmittance) is determined prior to clot time or prior to a preselected time period, whichever is less. As can be seen in FIG. 11, when transmittance is used for determining e.g. DIC, there is poor specificity and sensitivity. However, as can be seen in FIG. 9, when slope prior to initiation of clot formation is used, specificity and sensitivity are greatly improved, and are better than standard tests used in the diagnosis of Haemostatic Dysfunction, such as DIC.
  • [0059]
    Additional testing was performed on three sets of patients. The first set consisted of 91 APTT assays run on samples from 51 different confirmed DIC patients. The second set of data consisted of 110 APTT assays run on samples from 81 different confirmed normal patients. The third set of data included 37 APTT assays run on 22 abnormal, non-DIC samples. FIG. 5 illustrates ROC plots for the prediction of DIC for three different parameters derived from the APTT assay using the combined data sets described: (1) transmittance at 25 seconds (TR25), (2) APTT clot time, and (3) slope 1 (the slope up to initiation of clot formation). Slope 1 exhibited the best predictive power, followed by TR25. It has also been shown that transmittance at 18 seconds has predictive value, particularly when the APTT clot time is less than 25 seconds. The “cutoffs” associated with the highest efficiency for the three parameters are listed in Table 4:
    TABLE 4
    Parameter Cutoff
    TR25 <9700
    Clot Time >35
    Slope 1 <−0.0003
  • [0060]
    It should be noted that these cutoffs have shifted with the addition of the third set, and would likely shift again, depending on the sample populations. FIGS. 6 and 7 show the histograms for the DIC, normal and abnormal/non-DIC populations for TR25 and slope 1 respectively. Tables 5 and 6 show the data for the histograms in FIGS. 6 and 7 respectively:
    TABLE 5
    Bins DIC Normal Abnormal/Non-DIC
    −0.006  3 0 0
    −0.005  2 0 0
    −0.004  1 0 0
    −0.003  10 0 0
    −0.002  24 0 0
    −0.001  33 0 0
    −0.0005 12 0 0
    −0.0002 5 5 2
    −0.0001 1 37 13
    More 0 68 22
  • [0061]
    [0061]
    TABLE 6
    Bin DIC Normal Abnormal/Non-DIC
    7000 34 1 0
    8000 18 2 0
    9000 26 6 1
    9500 8 3 0
    9600 3 2 1
    9700 1 0 0
    9800 1 3 0
    9900 0 21 4
    10000  0 62 30
    More 0 10 1
  • [0062]
    [0062]FIGS. 8 and 10 show the group distributions for Slope 1 and TR25 respectively; and FIGS. 9 and 11 show the group distributions for Slope 1 and TR25 respectively. FIGS. 9 and 11 show partial subpopulations of the data shown in FIGS. 8 and 10.
  • [0063]
    When the prediction of Haemostatic Dysfunction is performed on an automated or semi-automated analyzer, the detected bi-phasic waveform can be flagged. In this way, the operator of the machine, or an individual interpreting the test results (e.g. a doctor or other medical practitioner) can be alerted to the existence of the biphasic waveform and the possibility/probability of Haemostatic Dysfunction such as DIC. The flag can be displayed on a monitor or printed out. A slope of less than about −0.0003 or less than about −0.0005 is the preferred cutoff for indicating a bi-phasic waveform. An increasing steepness in slope prior to clot formation correlates to disease progression.
  • [0064]
    The above examples show that waveform analysis on the APTT assay can identify characteristic bi-phasic patterns in patients with haemostatic dysfunction. In the majority of cases, this dysfunction could be labelled as DIC. This diagnostic waveform profile was seen in all APTT reagents tested, which were either silica or ellagaic acid-based. It has also been surprisingly found that a bi-phasic waveform can also be seen on PT assays with particular reagents, and that the bi-phasic waveform is likewise indicative of haemostatic dysfunction, primarily DIC.
  • [0065]
    Using samples that give bi-phasic APTT waveforms, the PT waveform profile was derived using PT reagents (thromboplastin), namely Recombiplast™ (Ortho), Thromborel™ (Dade-Behring) and Innovin™ (Dade-Behring). Both Recombiplast and Thromborel were particularly good at showing bi-phasic responses. Innovin was intermediate in its sensitivity. Using the transmittance level at 10 seconds into the PT reaction as the quantitative index, Recombiplast and Thromborel objectively showed lower levels of light transmittance than Innovin. Thromborel can show a slight increase in initial light transmittance before the subsequent fall. This may be, in part, related to the relative opaqueness of Thromborel.
  • [0066]
    Further studies were performed comparing ABTT profiles using Platelin™ and PT waveform profiles using Recombiplast™. Consecutive samples over a four week period from the intensive care unit were assessed. Visually, and on objective scores (comparing TL18 for APTT and TL10 for PT), the APTT profile was more sensitive to changes of haemostatic dysfunction and clinical progression than the PT profile. This relative sensitivity can be seen in the APTT profile of FIG. 12 (Platelin) compared to the PT profiles of FIG. 13 (Recombiplast) and FIG. 14 (Thromborel S). Invariably, at smaller changes in light transmittance, the APTT waveform detected abnormalites more easily than the PT waveform. Nonetheless, in severe degrees of haemostatic dysfunction, both bi-phasic profiles were concordant.
  • [0067]
    In a further embodiment of the invention, the time dependent measurement, such as an optical transmittance profile, can be performed substantially or entirely in the absence of clot formation. In this embodiment, a reagent is added which causes the formation of a precipitate, but in an environment where no fibrin is polymerized. The reagent can be any suitable reagent that will cause the formation of a precipitate in a sample from a patient with haemostatic dysfunction, such as DIC. As an example, divalent cations, preferably of the transition elements, and more preferably calcium, magnesium, manganese, iron or barium ions, can be added to a test sample. These ions cause activation of an atypical waveform that can serve as an indicator of haemostatic dysfunction. It is also possible to run this assay in the absence of a clotting reagent (APTT, PT, or otherwise). As part of the reagent that comprises the activator of the atypical waveform, or separately in another reagent, can also be provided a clot inhibitor. The clot inhibitor can be any suitable clot inhibitor such as hirudin, PPACK, heparin, antithrombin, I2581, etc. The formation of the atypical waveform can be monitored and/or recorded on an automated analyzer capable of detecting such a waveform, such as one that monitors changes in turbidity (e.g. by monitoring changes in optical transmittance).
  • [0068]
    [0068]FIG. 15 is an illustration of two waveforms: waveform (x) is a test run on a sample using an APTT clotting reagent and resulting in an atypical (biphasic) waveform, whereas waveform (y) is a test run on a sample where a clot inhibitor is used (along with a reagent, such as a metal divalent cation, which causes the formation of a precipitate in the sample). Waveform (y) is exemplary of a waveform that can result in patients with haemostatic dysfunction where no clotting reagent is used and/or a clot inhibitor is added prior to deriving the time-dependent measurement profile. Generally speaking, the greater the slope of the waveform (the larger the drop in transmittance in the same period of time) due to the precipitate formation, the greater severity of the patient's haemostatic dysfunction. FIG. 16 is a standard curve for ELISA of CRP (CRP isolated from a patient used as the standard).
  • [0069]
    The precipitate formed in the present invention was isolated and characterized by means of chromatography and purification. Gel Filtration was performed as follows: A column (Hiprep Sephacryl S-300 High resolution—e.g. resolution of 10 to 1500 kDa) was used. The volume was 320 ml (d=26 mm, 1=600 mm), and the flow rate was 1.35 ml/min. FIG. 17 shows the isolated precipitate.
  • [0070]
    [0070]FIG. 18 is a graph showing the time course of turbidity in a sample upon adding a precipitate inducing agent (in this case divalent calcium) and a thrombin inhibitor (in this case PPACK) to mixtures of patient and normal plasmas. FIG. 19 is a graph showing the relationship between maximum turbidity change and amount of patient plasma in one sample. 0.05 units implies 100% patient lasma. (Data from FIG. 18).
  • [0071]
    The steps used in the purification of components involved in the turbidity change in a patient's plasma were as follows: PPACK (10 μM) was added to patient plasma. Calcium chloride was added to 50 mM, followed by 8 minutes of incubation, followed b the addition of EtOH to 5%. The sample was then centrifuged 10,500g for 15 inutes at 4 degrees Celsius. The pellet was then dissolved in HBS/1 mM citrate/10 μM PPACK, followed by 35-70% (NH4)2SO4 fractionation. Finally, sepharose chromatography was performed using a 5 ml bed, 0.02-0.5M NaCl gradient and 50 ml/side, to collect 2 ml fractions. FIG. 20 shows the results of anion exchange chromatography (Q-sepharose) of material recovery after the 35-70% ammonium sulfate fractionation of patient plasma.
  • [0072]
    [0072]FIGS. 21a and 21 b show the non-reduced and reduced, respectively, SDS PAGE of various fractions obtained upon fractionation of patient plasma. The loading orientation (left to right): 5-15% gradient/Neville Gel. (approximately 10 μg protein loaded per well). In lane 1 are molecular weight standard (94, 67, 45, 30, 20 and 14 kDa from top to bottom. In lane 2 is 35% (NH4)2SO4 pellet, whereas in lane 3 is 70% (NH4)2SO4 supernate. Lane 4 is Q-sepharose starting material. Also shown in FIGS. 21a and b are (from FIG. 20) peaks 1, 2 a, 2 b and 3 in, respectively, lanes 5, 6, 7 and 8. Lane 9 is pellet 1, whereas in lane 10 are again, molecular weight standards. Results of NH2-terminal sequencing showed peak 3, the 22 kD protein in lanes 8 and 9 to be C-reactive protein (CRP), and the 10 kD protein in lane 9 to be human serum amyloid A (SAA). Peak 1 in lane 5 is a 300 kD protein which, as can be seen in FIG. 23, is part of the complex of proteins (along with CRP) in the precipitate formed due to the addition of a metal divalent cation to a plasma sample.
  • [0073]
    Immunoblots of CRP were performed in normal and DIC plasma. Blot 1 (see FIG. 22): (used 0.2 μl plasmas for reducing SDS-PAGE/CRP Immunoblotting). Loading orientation (left to right): NHP; Pt 5; 3; 1; 2; 4; and 8. For Blot 2: Loading orientation (left to right): NHP; Pt 9; 10; 11; 7; 6; 12. For Blot 3: (CRP purified from DIC patient plasma)—Loading orientation (left to right; ng CRP loaded): 3.91; 7.81; 15.625; 31.25; 62.5; 125; 250. The Blots were blocked with 2% (w/v) BSA in PBS, pH 7.4 and then sequentially probed with rabbit anti-human CRP-IgG (Sigma, Cat# C3527, dil 1:5000 in PBS/0.01% Tween 20) and then treated with the same antibody conjugated to HRP (dil 1:25000 in PBS/0.01% Tween 20).
  • [0074]
    [0074]FIG. 23 illustrates the turbidity changes upon adding divalent calcium to materials obtained upon Q-sepharose chromatography in the absence of plasma. No single peak gave a positive response, but a mixture of peak 1 and peak 3 materials did give a positive response indicating the involvement of CRP, a 300 kD protein, and one or more other proteins in the precipitate (peak 3+plasma was the control). FIG. 24 is a table showing CRP, μg/ml determined by ELISA. Delta A405 nm is the maximum turbidity change observed when patients' plasma was recalcified on the presence of the thrombin inhibitor PPACK). FIG. 24, therefore, shows that patients with increased absorbance have varying elevated levels of CRP, once again indicating that more than one protein is involved in the precipitate formation.
  • [0075]
    In one embodiment of the invention, the reagent to plasma ratio is varied between multiple tests using a reagent that induces precipitate formation. This variance allows for amplifying the detection of the precipitate formation by optimization of reagent to plasma ratio (e.g. varying plasma or reagent concentrations). In the alternative, the slope due to the precipitate formation can be averaged between the multiple tests. As can be seen in FIG. 25, the response to increasing calcium concentrations is shown in optical transmission waveform profiles. The left panels show two normal patients where calcium concentrations were varied (no clotting agents used), whereas the right panels show two patients with haemostatic dysfuntion (DIC in these two cases) where the metal cation (calcium) concentration was varied (the calcium alone being incapable of any substantial fibrin polymerization).
  • [0076]
    Though precipitate formation is capable of being detected in patients with haemostatic dysfunction when a clotting agent is used, it is beneficial that the reagent used is capable of forming the precipitate without fibrin polymerization. As can be seen in FIG. 26, the slope is more pronounced and more easily detectable when a reagent such as calcium chloride is used (right panel) as compared to when a clotting reagent such as an APTT reagent (left panel) is used. As can be seen in FIG. 27, when a clot inhibitor was added (in this case heparin), all parameters including slope_1 gave good results, and slope_1 showed the best sensitivity. For the above reasons, a reagent capable of precipitate formation in the absence of fibrin polymerization and/or a clot inhibitor are preferred.
  • [0077]
    As can be seen in FIG. 28, CRP levels from 56 ITU patients were plotted against transmittance at 18 seconds. The dotted line is the cut-off for an abnormal transmittance at 18 seconds. FIG. 29 shows more samples with CRP and decrease in transmittance at 18 seconds (10000-TR18). These figures indicate that patients with abnormal transmittance levels due to precipitate formation all have increased levels of CRP. However, not all patients with increased levels of CRP have abnormal transmittance levels thus indicating that more than CRP is involved in the precipitate.
  • [0078]
    In a further embodiment of the invention, the formation of the precipitate comprising a complex of proteins including CRP is detected and/or quantitated, by the use of a latex agglutination assay. In this method, antibodies are raised against wither the 300 kD protein or CRP. Whether monoclonal or polyclonal antibodies are used, they are bound to suitable latex and reacted with a patient test sample or preferably with the precipitate itself having been separated from the rest of the patient plasma, in accordance with known methods. The amount of agglutination of the latex is proportional to the amount of the CRP complex in the sample.
  • [0079]
    Alternatively, immunoassays can be performed, such as ELISA's, according to known methods (sandwich, competition or other ELISA) in which the existence and/or amount of the complex of proteins is determined. For example, an antibody bound to solid phase binds to CRP in the CRP protein complex. Then, a second labeled antibody is added which also binds to CRP in the CRP protein complex, thus detecting the complex of proteins. In the alternative, the second labeled antibody can be specific for the 300 kD protein in the complex. Or, in a different assay, the antibody bound to solid phase can bind to the 300 kD protein in the complex, with the second (labeled) antibody binding either to the 300 kD protein or to CRP. Such immunoassays could likewise be adapted to be specific for SAA, where antibodies, bound and labeled, bind to SAA, or where one antibody binds to SAA and the other either to CRP or the 300 kD protein. The above techniques are well known to those of ordinary skill in the art and are outlined in Antibodies, A Laboratory Manual, Harlow, Ed and Lane, David, Cold Spring Harbor Laboratory, 1988, the subject matter of which is incorporated herein by reference.
  • [0080]
    It is to be understood that the invention described and illustrated herein is to be taken as a preferred example of the same, and that various changes in the methods of the invention may be resorted to, without departing from the spirit of the invention or scope of the claims.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2458287 *31 Aug 19444 Jan 1949Signode Steel Strapping CoSnubber plate
US3307392 *4 May 19647 Mar 1967Research CorpAutomatic prothrombin timer apparatus and method
US3658480 *13 Apr 197025 Apr 1972Bio Data CorpCoagulation timing apparatus, and method
US4040788 *5 Apr 19769 Aug 1977Sanford L. SimonsApparatus, instrumentation, and method for comparing samples
US4047890 *21 Mar 197513 Sep 1977Bio/Data CorporationMethod and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas
US4157871 *16 May 197712 Jun 1979Beckman Instruments, Inc.System for rate immunonephelometric analysis
US4199748 *3 Feb 197822 Apr 1980Rush-Presbyterian-St. Luke's Medical CenterAutomated method and apparatus for classification of cells with application to the diagnosis of anemia
US4217107 *22 Sep 197812 Aug 1980Sankyo Company Ltd.Method of measuring blood clotting time
US4279616 *29 Aug 197921 Jul 1981Sankyo Company LimitedMethod for measuring blood coagulation and device therefor
US4289498 *8 Jan 197915 Sep 1981Ortho Diagnostics, Inc.One-stage prothrombin assay and compositions useful therein
US4362531 *14 Apr 19817 Dec 1982Technicon Instruments CorporationAgglutination immunoassays carried out with agent to reduce non-specific interferences
US4766083 *4 Apr 198323 Aug 1988Wako Pure Chemical Industries, Ltd.Method for the photometric determination of biological agglutination
US4782014 *16 Jun 19861 Nov 1988Ciba-Geigy CorporationAssay and purification of amyloid components, applications, and kits therefor
US4902630 *14 Jul 198820 Feb 1990Abbott LaboratoriesFluorescence polarization immunoassy and reagents for measurement of c-reactive protein
US4965725 *8 Apr 198823 Oct 1990Nueromedical Systems, Inc.Neural network based automated cytological specimen classification system and method
US4998535 *5 Sep 198912 Mar 1991Univ. of Washington New England Medical Center Hospitals, Inc.Thrombolysis predictive instrument
US5003065 *14 Jun 198826 Mar 1991Carey MerrittCompounds and process for measuring c-reactive protein
US5055412 *21 Mar 19898 Oct 1991Proksch Gary JFactor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same
US5156974 *27 May 198820 Oct 1992Biodata CorporationMethod for determining the fibrinogen level of a blood sample
US5169786 *19 Dec 19898 Dec 1992Ortho Diagnostic Systems, Inc.Method of determining levels of extrinsic and intrinsic clotting factors and protein c
US5218529 *30 Jul 19908 Jun 1993University Of Georgia Research Foundation, Inc.Neural network system and methods for analysis of organic materials and structures using spectral data
US5221628 *19 Mar 199122 Jun 1993Northwestern UniversityBinding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5262303 *11 Oct 199016 Nov 1993Trustees Of Boston UniversityLigand/anti-ligand assays for adherent proteins
US5358852 *21 Dec 199225 Oct 1994Eastman Kodak CompanyUse of calcium in immunoassay for measurement of C-reactive protein
US5388164 *19 Aug 19927 Feb 1995Olympus Optical Co., Ltd.Method for judging particle agglutination patterns using neural networks
US5473551 *24 Feb 19945 Dec 1995Sato; TakeshiAutomatic analyzer
US5473732 *7 Feb 19955 Dec 1995Chang; Hou-Mei H.Relational artificial intelligence system
US5500345 *16 Dec 199419 Mar 1996Iatron Laboratories, Inc.Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein
US5506146 *28 Jun 19949 Apr 1996Stiftung Fur Diagnostische ForschungMeasurement of the activated partial thromboplastin time (APTT) in a one-step reaction
US5525477 *20 Sep 199411 Jun 1996Board Of Trustees Operating Michigan State UniversityMethod for diagnosing blood clotting disorders
US5526111 *31 Aug 199311 Jun 1996Boehringer Mannheim CorporationMethod and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control
US5536640 *29 Oct 199316 Jul 1996Trustees Of Boston UniversityLigand/anti-ligand assays for adherent proteins
US5553616 *30 Nov 199310 Sep 1996Florida Institute Of TechnologyDetermination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator
US5563983 *8 May 19958 Oct 1996Fujitsu LimitedLearning system operated through a layered neural network
US5567596 *29 Dec 199422 Oct 1996Research Foundation Of State University Of New YorkRapid assay of activators and inhibitors of clotting
US5591403 *18 Mar 19967 Jan 1997International Technidyne CorporationPortable prothrombin time test apparatus and associated method of performing a prothrombin time test
US5593897 *6 Jul 199414 Jan 1997Northwestern UniversityBinding of immune complexes by modified forms of C-reactive protein
US5646045 *17 May 19958 Jul 1997Protein Technologies InternationalCellulose in food matrix quantification
US5670329 *28 May 199323 Sep 1997Cardiovascular Diagnostics, Inc.Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field
US5705395 *14 Nov 19946 Jan 1998The Scripps Research InstituteMethod for diagnosis of thrombotic disorders
US5708591 *7 Jun 199513 Jan 1998Akzo Nobel N.V.Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US5715821 *7 Dec 199510 Feb 1998Biofield Corp.Neural network method and apparatus for disease, injury and bodily condition screening or sensing
US5716795 *3 Jan 199610 Feb 1998Matschiner; John T.Thrombomodulin-based coagulometric assay of the protein C system
US5834223 *18 Dec 199710 Nov 1998The Scripps Research InstituteMethod for diagnosis of thrombotic disorders
US5856114 *26 Feb 19965 Jan 1999The University Of VermontImmunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings
US5862304 *31 Oct 199019 Jan 1999Board Of Regents, The University Of Texas SystemMethod for predicting the future occurrence of clinically occult or non-existent medical conditions
US5981285 *31 Jul 19989 Nov 1999Carroll; Wallace E.Method and apparatus for determining anticoagulant therapy factors
US6010911 *30 Apr 19974 Jan 2000Medtronic, Inc.Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6040147 *2 Apr 199821 Mar 2000The Brigham And Women's Hospital, Inc.Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US6101449 *21 May 19978 Aug 2000Akzo Nobel N.V.Method for predicting the presence of congenital and therapeutic conditions from coagulation screening assays
US6156530 *8 Nov 19955 Dec 2000Global Hemostasis Institute Mgr AbMethod for analysis of haemostatic activity
US6242265 *20 May 19945 Jun 2001Dade Behring Marburg GmbhUse of doubly or triply charged cations in immunochemical assays
US6269313 *2 Mar 200031 Jul 2001Akzo Nobel N.V.Method for predicting the presence of congenital and therapeutic conditions from coagulation screening assays
US6321164 *31 Dec 199720 Nov 2001Akzo Nobel N.V.Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6429017 *12 Aug 19996 Aug 2002BiomerieuxMethod for predicting the presence of haemostatic dysfunction in a patient sample
US20020193949 *8 Jun 200119 Dec 2002Fischer Timothy JMethod for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US763268528 Dec 200615 Dec 2009Becton, Dickinson And CompanyMethod of predicting the onset of sepsis in SIRS-positive individuals using mass spectrometry
US764557312 Nov 200312 Jan 2010Becton, Dickinson And CompanyDiagnosis of sepsis or SIRS using biomarker profiles
US764561328 Dec 200612 Jan 2010Becton, Dickinson And CompanyMass spectrometry techniques for determining the status of sepsis in an individual
US776739514 Apr 20063 Aug 2010Becton, Dickinson And CompanyDiagnosis of sepsis
US854893513 Feb 20091 Oct 2013Orion Diagnostica OyPredicting a future property using reagents by measuring properties at points in time
US970866118 Jun 201518 Jul 2017Becton, Dickinson And CompanyAdvanced detection of sepsis
US20040096917 *12 Nov 200320 May 2004Becton, Dickinson And CompanyDiagnosis of sepsis or SIRS using biomarker profiles
US20040097460 *12 Nov 200320 May 2004Becton, Dickinson And CompanyDiagnosis of sepsis or SIRS using biomarker profiles
US20040157242 *12 Nov 200312 Aug 2004Becton, Dickinson And CompanyDiagnosis of sepsis or SIRS using biomarker profiles
US20060147998 *30 Nov 20056 Jul 2006Jones Gregory RMethod for diagnosing and monitoring critically ill patients
US20060157647 *18 Jan 200520 Jul 2006Becton, Dickinson And CompanyMultidimensional liquid chromatography/spectrometry
US20080050829 *28 Dec 200628 Feb 2008Becton, Dickinson And CompanyUse of mass spectrometry to detect sepsis
US20080138832 *25 Sep 200712 Jun 2008Becton, Dickinson And CompanyDiagnosis of sepsis or SIRS using biomarker profiles
US20110016073 *13 Feb 200920 Jan 2011Orion Diagnostica OyMethod for predicting a future property
US20110105350 *7 May 20105 May 2011Becton, Dickinson And CompanyDiagnosis of sepsis
Classifications
U.S. Classification436/69, 600/369, 422/73, 435/13, 436/501, 436/74, 436/84, 436/79, 436/86, 422/82.09, 436/73, 435/7.1, 436/164
International ClassificationA61P7/04, G01N33/50, A61B5/1455, G01N33/48, G01N33/15, A61B5/145, G01N33/53, G06F19/00, G01N33/86, G01N33/49
Cooperative ClassificationG01N30/96, G01N33/4905, G01N33/86
European ClassificationG01N33/86, G01N33/49B